Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of specific share plan adjustments rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of the notional investment held within the GSK 401K plan, which is notionally held in GSK American Depositary Shares (ADSs). On February 28, 2014, at a price of $55.94 per ADS, the following increases in notional ADS allocations occurred:
- Dr M M Slaoui: Increase of 15 ADSs.
- Dr K Slaoui (Connected Person): Increase of 4 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Verify the impact of the GSK 401K plan revaluation on director holdings.
- Confirm the transaction date of February 28, 2014, and the notification date of March 3, 2014.
- Note the specific ADS price of $55.94 used for the notional allocation calculation.
- Identify the specific individuals involved: Dr M M Slaoui and Dr K Slaoui.